Company Profile
Aethlon Medical Stock Price, News & Analysis
- Ticker:
- AEMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.02 USD (-7.08%)
Close
Last updated: August 6, 2026
3.47M USD
Market cap
Why the stock is moving
Following the latest company update, “Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026”, AEMD closed down 7.67% at $3.25 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Clinical-Stage Medical Device Company
Aethlon Medical is developing the Hemopurifier, an extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles from blood. The company is pursuing applications in oncology, life-threatening viral infections, and other inflammation-associated diseases.
Hemopurifier Mechanism
The Hemopurifier combines plasma separation, size exclusion, and affinity binding using a plant-derived lectin resin that targets mannose-rich structures on extracellular vesicles and viral surfaces. Tumor-derived EVs are believed to contribute to metastasis and resistance to immunotherapy and chemotherapy.
Oncology and Infectious Disease Platform
The same extracorporeal filtration approach may be applicable across diseases involving circulating pathogenic particles. Aethlon is currently prioritizing tumor-derived EV removal in oncology while retaining potential applications in severe enveloped viral infections.
Oncology Development Path
Aethlon is conducting an Australian study in patients with solid tumors whose disease is stable or progressing on anti-PD-1 therapy. The first two dose cohorts have been completed, and treatment has begun in the third and final cohort.
Future catalysts
Completion of enrollment and analysis of all dosing regimens in Cohort 3 of the Australian oncology study are the next clinical milestones.
Cohort 3 results are expected to help define the optimal Hemopurifier treatment regimen and guide future oncology development.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aethlon Medical (AEMD)?
Aethlon Medical (AEMD) most recently closed at 3.02 USD, a -7.08% move versus the previous session.
What is the market cap of Aethlon Medical (AEMD)?
Aethlon Medical currently has a market capitalization of 3.47M USD on BioPharmSignal.
What does Aethlon Medical do?
Clinical-Stage Medical Device Company Aethlon Medical is developing the Hemopurifier, an extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles from blood. The company is pursuing applications in oncology, life-threatening viral infections, and other inflammation-associated diseases. Hemopurifier Mechanism The...
On which exchange is AEMD stock listed?
Aethlon Medical (AEMD) is associated with NASDAQ, United States, Biopharma.
What is PD-1?
Oncology Development Path Aethlon is conducting an Australian study in patients with solid tumors whose disease is stable or progressing on anti-PD-1 therapy.
Which conditions is Aethlon Medical targeting with PD-1?
Aethlon Medical is associated with oncology, inflammatory disease based on its company overview and current catalyst commentary.
How does Aethlon Medical describe recent progress with PD-1?
Completion of enrollment and analysis of all dosing regimens in Cohort 3 of the Australian oncology study are the next clinical milestones. Cohort 3 results are expected to help define the optimal Hemopurifier treatment regimen and guide future oncology development.
What is Clinical-Stage?
Clinical-Stage Medical Device Company Aethlon Medical is developing the Hemopurifier, an extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles from blood.